Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145768

Pw145768 View Pathway
drug action

Triclofos Drug Metabolism Action Pathway

Homo sapiens

PW145832

Pw145832 View Pathway
drug action

Triclosan Drug Metabolism Action Pathway

Homo sapiens

PW145824

Pw145824 View Pathway
drug action

Triethylenetetramine Drug Metabolism Action Pathway

Homo sapiens

PW146558

Pw146558 View Pathway
drug action

Trifarotene Drug Metabolism Action Pathway

Homo sapiens

PW176155

Pw176155 View Pathway
metabolic

Trifarotene Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Trifarotene are predicted with biotransformer.

PW128161

Pw128161 View Pathway
drug action

Trifluoperazine Dopamine Antagonist Action Pathway

Homo sapiens
Trifluoperazine is a trifluoro-methyl phenothiazine derivative. Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. It is indicated for the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.

PW144937

Pw144937 View Pathway
drug action

Trifluoperazine Drug Metabolism Action Pathway

Homo sapiens

PW128212

Pw128212 View Pathway
drug action

Triflupromazine - Dopamine Antagonist Action Pathway

Homo sapiens
Triflupromazine is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B). Dopamine hypothesis states that dopamine abnormalities in the mesolimbic and prefrontal brain regions exist in schizophrenia.

PW144628

Pw144628 View Pathway
drug action

Triflupromazine Drug Metabolism Action Pathway

Homo sapiens

PW128090

Pw128090 View Pathway
drug action

Triflupromazine Mechanism of Action Action Pathway

Homo sapiens
Triflupromazine is a member of a class of drugs called phenothiazines, which are dopamine D1/D2 receptor antagonists. Triflupromazine is used particularly to control violent behavior during acute episodes of psychotic disorders. It can also be used to control severe nausea and vomiting, severe hiccups, and moderate to severe pain in some hospitalized patients. Triflupromazine acts on the central nervous system. The mechanism of the anti-emetic effect is due predominantly to blockage of the dopamine D2 neurotransmitter receptors in the chemoreceptor trigger zone (CTZ) and vomiting centre. Triflupromazine blocks the neurotransmitter dopamine and the vagus nerve in the gastrointestinal tract. Triflupromazine also binds the muscarinic acetylcholine receptors (M1 and M2) and the tryptamine D receptors (5HT2B). Dopamine hypothesis states that dopamine abnormalities in the mesolimbic and prefrontal brain regions exist in schizophrenia.